Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat to Be Filed in US in Early 2021
Akebia Therapeutics’ oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor vadadustat, which is under codevelopment with Otsuka Pharmaceutical outside Japan, hit its primary and secondary efficacy endpoints in its two multinational PIII studies in adult patients on dialysis with anemia due…
To read the full story
Related Article
- Otsuka Ends Vadadustat Global License Deal with Akebia
May 16, 2022
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat Nixed in US
April 1, 2022
- Otsuka Files HIF-PH Inhibitor Vadadustat in Europe
November 1, 2021
- FDA Target Date for Vadadustat Set for March 29: Otsuka/Akebia
June 2, 2021
- Otsuka Partner Akebia Files HIF-PH Inhibitor Vadadustat in US
March 31, 2021
- Akebia/Otsuka's Vadadustat Hits Primary Target in Multinational PIII
May 8, 2020
BUSINESS
- Fuji Pharma Recalls Eylea Biosimilar Lots over Faulty Finger Grips
November 6, 2026
- Medipal Sets Dec. 15 Shareholder Meeting, Opposes Chairman’s Ouster
November 6, 2026
- Nitrosamine Impurities Reported for Generic Telmisartan; No Recalls Planned
November 6, 2026
- Bracco Japan to Acquire Iopamiron from Bayer in July 2027
November 6, 2026
- Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
November 5, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…